Median progression-free survival was 6 months.
中位无进展生存期为6个月。
The factors influencing disease-free survival are BVI, TNM and LNM.
影响无瘤生存期的因素为：BVI、TNM分期和N分期。
Coprimary end points were rates of overall and progression-free survival.
共同的初级终点指标为总生存率和无进展生存率。
In both studies, the primary efficacy endpoint was progression-free survival.
在两项研究中，主要功效评估指标是无进展生存期。
A limited number of genes were related to overall survival and cancer-free survival after LT.
有限数目的基因和全部生存率和肝移植后无癌生存率相联系。
Thus, patients with RCC who received vitespen after nephrectomy showed no increased recurrence-free survival.
因此，长期存活的肾切除术后接受噬菌体接种的肾细胞癌病人显示复发率并未增高。
In the extended disease-free survival in Integrated Treatment slight advantage, but there is no statistical significance.
在延长无病生存期方面中西医结合治疗略有优势，但尚无统计学意义。
Conclusions The IGS is strongly associated with metastasis-free survival and overall survival for four different types of tumors.
结论：在四种不同类型的肿瘤中，IGS和无转移生存期以及总体生存期紧密相关。
Furthermore, it improves the QoL and the nutritional status of affected patients with favorable overall and disease-free survival.
此外，它改善了总生存和无病生存患者的生活质量和营养状况。
RESULTS: The candidates' overall 3-year survival rate and recurrence-free survival rate were 67% and 70% after transplantation, respectively.
结果：在移植后，候选人全部3年存活率和无肿瘤复发存活率分别为67％、70％。
The primary end point was progression-free survival; secondary end points included the objective response rate, overall survival, and safety.
主要研究终点为无进展生存（PFS），次级研究终点包括客观有效率、总生存和安全性。
Cox proportional-hazards analysis of progression-free survival according to baseline characteristics favored sunitinib in all subgroups studied.
在研究的所有亚组中，根据基线特征进行的PFS的Cox风险比例分析均有利于舒尼替尼。
Multi-modal treatment like adjuvant androgen deprivation therapy plus radiotherapy can greatly improve the biochemical recurrence-free survival.
术后辅助内分泌治疗联合放疗的综合治疗可显著延长无生化复发生存时间。
Objective To investigate the relationship between immunophenotype and event-free survival (EFS) in children with acute lymphoblastic leukemia (ALL).
目的探讨儿童急性淋巴细胞白血病(all)免疫表型与无病生存期(EFS)的关系。
The median progression-free survival period with the drug combination was 11.8 months, twice as long as the 5.9 months achieved with paclitaxel alone.
药物联用的中值无进展存活期为11.8个月，是用单独紫杉醇获得的5.9个月的两倍。
Thus, surrogate endpoints like response rate and progression-free survival are commonly accepted, although all parties involved realize the risk involved.
因此，替代终点如反应率和无进展生存率被普遍接受，尽管各方意识到风险所在。
The two-year estimated disease free survival was much lower in children with high AS expression(53.8%)than in those with low AS expression(84.6%)(P<0.05).
AS低表达组患儿白血病持续完全缓解率为84.6%，而AS高表达组患儿持续完全缓解率仅为53.8%（P＜0.05）。
Objective to investigate the adverse effect, disease free survival and overall survival of dose-dense chemotherapy in postoperative breast cancer patients.
目的观察剂量密度化疗治疗乳腺癌的不良反应及对无病生存期和总生存期的影响。
Although the study was not designed to compare the Avastin doses, a similar treatment effect in progression-free survival was observed between the two arms.
虽然这项研究并不是用来比较阿瓦斯丁剂量，一项类似的治疗效果，在级数无生存观察到两国之间的武器。
Because the drugs reduce cancer recurrence, finding a way to help patients stay on them is important for long-term, relapse-free survival, according to Rastelli.
根据拉斯·泰利的说法，由于这种药物可以减少癌症的复发，因此寻找一条途径帮助这些患者长期无复发的生存下去是很重要的事情。
Univariate prognostic evaluation showed that tumor size, nodal involvement, histological grade, CA15 3 and CEA were prognostic factors in disease-free survival.
单变量预后评价显示：肿瘤的大小、淋巴结浸润、组织型别、CEA、CA153等是无病存活的预后要素。
KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild type stage III colon cancers from an adjuvant chemotherapy trial (N0147 Alliance).
【译】KRAS基因密码子12和13与无病生存的野生型BRAF的II I期结肠癌辅助化疗试验从一个突变(n0147联盟)。
The primary objective of the study was to demonstrate superiority in progression-free survival of both Avastin containing treatment arms versus the control regimen.
这项研究的主要目的是，要表现出优势，循序渐进无生存的阿瓦斯丁都含有治疗武器银两控制水情。
However, neither overall survival after the start of antitumor therapy nor progression-free survival after gefitinib therapy was significantly different between groups.
然而，无论是抗肿瘤治疗开始后的整体生存率，还是吉非替尼治疗后无恶化生存率在上述两组病人中并无明显差异。
FDA gave its blessing based on a trial showing it offered breast cancer patients an extra 5.5 months of "progression-free survival," time when their tumors weren't growing.
FDA是基于阿瓦斯丁可以让患者的肿瘤在5个半月内都不增长的研究，批准了阿瓦斯丁的使用许可。
First results from a French study comparing single versus double autologous transplantation have shown a benefit in terms of event-free survival for the sequential approach.
最先的一项来自法国的研究结果表明，比较单自体移植对双自体移植，对在后继的无病生存方面的研究有帮助。
Objective To analyse the treatment outcome of 158 childhood acute lymphoblastic leukemia (ALL) patients, and explore how to improve the event-free survival(EFS) rate in ALL.
目的对15 8例儿童急性淋巴细胞白血病（ALL）患儿治疗结果进行分析，探讨如何进一步提高儿童ALL无事件生存（EFS）率。
Conclusions This study suggests that tumor recurrence decreases and tumor free survival increases by adjuvant individualized chemotherapy after liver transplantation for HCC.
结论肝移植术后辅助个体化化疗能显著降低肝癌肝移植术后的肿瘤复发率 ，明显延长肝移植术后的无瘤生存时间。
Conclusions This study suggests that tumor recurrence decreases and tumor free survival increases by adjuvant individualized chemotherapy after liver transplantation for HCC.
结论肝移植术后辅助个体化化疗能显著降低肝癌肝移植术后的肿瘤复发率 ，明显延长肝移植术后的无瘤生存时间。
应用推荐